Pathophysiological roles for purines
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The motor symptoms of Parkinson's disease (PD) are due primarily to the degeneration of the dopaminergic neurons in the nigrostriatal pathway. However, several other brain areas and neurotransmitters other than dopamine such as noradrenaline, 5-hydroxytryptamine and acetylcholine are affected in the disease. Moreover, adenosine because of the extensive interaction of its receptors with the dopaminergic system has been implicated in the in the pathophysiology of the disease. Based on the involvement of these nondopaminergic neurotransmitters in PD and the sometimes severe adverse effects that limit the mainstay use of dopamine-based antiparkinsonian treatments, recent assessments have called for a broadening of therapeutic options beyond the traditional dopaminergic drug arsenal. In this review we describe the interactions between dopamine and adenosine receptors that underpin the preclinical and clinical rationale for pursuing adenosine A2A receptor antagonists as symptomatic and potentially neuroprotective treatment of PD. The review will pay particular attention to recent results regarding specific A2A receptor-receptor interactions and recent findings identifying urate, the end product of purine metabolism, as a novel prognostic biomarker and candidate neuroprotectant in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Willett, W. C. (1998) · doi:10.1093/acprof:oso/9780195122978.001.0001 · Cited by 4,541
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 1×
“The Finnish population is of particular interest since it exhibits one of the world’s highest rates of coffee consumption (Fredholm et al., 1999).”
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 2×
“…of PD patients, whereas most recent studies have reported a more widespread distribution of activated microglia in the brain, both in early and in late stages of the disease, involving pons, basal ganglia, striatum and frontal and temporal cortex (Gerhard et al., 2006; Mc Geer and McGeer, 2008).”
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 11×
“The studies represented documented cases from North Amer ica, Europe and Asia.”
InfluentialUric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid
Davies, K. J. A., Sevanian, A., Muakkassah-Kelly, S. F., & Hochstein, P. (1986) · Biochemical Journal · doi:10.1042/bj2350747 · Cited by 558 · cited 2×
“It has been shown to scavenge peroxynitrite as well as oxygen free radi cals in vitro (Franzoni et al., 2006; Whiteman et al., 2002) and displays potent iron-chelating activity independent of its direct antioxidant action (Davies et al., 1986).”
Adenosine: does it have a neuroprotective role after all?
de Mendonça, A., Sebastião, A. M., & Ribeiro, J. A. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00033-3 · Cited by 248 · cited 1×
“…role of adenosine has also been demonstrated, suggesting that blockade of adenosine receptors may confer neuroprotection across a range of neurodegenerative disorders (Chen et al., 1999; de Mendonca et al., 2000; Jones et al., 1998; Melani et al., 2003; Pinna et al., 2010; Popoli et al., 2002).”
Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: A case-control study
Benedetti, M. D., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2000) · Neurology · doi:10.1212/wnl.55.9.1350 · Cited by 234 · cited 3×
“…dietary factor most consistently linked to an altered risk of PD, with greater con sumption associated with a reduced risk (Ascherio et al., 2001; Benedetti et al., 2000; Checkoway et al., 2002; Fall et al., 1999; Hellenbrand et al., 1996; Hu et al., 2007; Ragonese et al., 2003; Ross et al.,…”
InfluentialAscherio, A. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh312 · Cited by 232 · cited 1×
“In two separate prospective studies (Ascherio et al., 2003, 2004) they showed that amongst women who did not use post-menopausal oestro gens, caffeine was in fact associated with a reduc tion in the risk of subsequent PD (just as in men).”
Cited by
Epidemiology of Parkinson's disease
Elbaz, A., Carcaillon, L., Kab, S., & Moisan, F. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2015.09.012 · Cited by 445
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Purinergic signalling: From normal behaviour to pathological brain function
Burnstock, G., Krügel, U., Abbracchio, M. P., & Illes, P. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.006 · Cited by 397
Blesa, J., Trigo-Damas, I., Dileone, M., del Rey, N. L.-G., Hernandez, L. F., & Obeso, J. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.002 · Cited by 256
Caffeine as a factor influencing the functioning of the human body-friend or foe?
Rodak, K., Kokot, I., & Kratz, E. M. (2021) · Nutrients · doi:10.3390/nu13093088 · Cited by 188
Metadata
- Authors
- Morelli, M., Carta, A. R., Kachroo, A., & Schwarzschild, M. A.
- Venue
- Progress in Brain Research
- Publisher
- Elsevier
- Published
- 2010
- Volume
- 183
- Pages
- 183-208
- ISSN
- 0079-6123 (ISSN-L)
- OpenAlex
- W1605590717
- Cited by
- 93
- References
- 12
- FWCI
- 17.52
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathophysiological roles for purines. https://app.cochat.ai/papers/10.1016/s0079-6123(10)83010-9
- The paper
- Morelli, M., Carta, A. R., Kachroo, A., & Schwarzschild, M. A. (2010). Pathophysiological roles for purines. Progress in Brain Research. https://doi.org/10.1016/s0079-6123(10)83010-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.